G Passot1, N Bakrin2, S Isaac3, E Decullier4, F N Gilly1, O Glehen5, E Cotte1. 1. Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Oncologic and General Surgery, France; UMR 37-38 Université Lyon 1, Lyon, France. 2. UMR 37-38 Université Lyon 1, Lyon, France; Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Gynecology Department, France. 3. Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Pathology, France. 4. Hospices Civils de Lyon, Pole IMER, Lyon, France; Health Information and Clinical Research, France. 5. Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Oncologic and General Surgery, France; UMR 37-38 Université Lyon 1, Lyon, France. Electronic address: olivier.glehen@chu-lyon.fr.
Abstract
BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are considered the only curative treatment for many peritoneal surface malignancies. The purpose of this study was to evaluate feasibility and safety of CRS combined with HIPEC by laparoscopy for patients with limited peritoneal disease and to compare postoperative outcomes with those for an open procedure. METHODS: Between January 2011 and November 2012, all patients with low-grade pseudomyxoma peritonei (PMP) or multicystic mesothelioma (MM) and limited peritoneal disease (Peritoneal Cancer Index [PCI] less than 10) underwent CRS and HIPEC by a laparoscopic approach. The study cohort was matched with a historical cohort of patients with the same characteristics (completeness of cytoreduction, HIPEC agent, PCI ± 11 and age ± 20 years) treated with CRS and HIPEC by laparotomy. RESULTS: Eight patients (five low-grade PMP and three MM) treated by a laparoscopic approach were compared to eight patients treated by laparotomy. All patients underwent complete cytoreductive surgery with HIPEC, and no conversion to laparotomy was needed. The median surgical length was 210 min (150-300) vs 240 (210-360), with a median hospital stay of 12 days (9-18) vs 19 (13-33). One patient had a postoperative complication (intraperitoneal haematoma treated by radiological drainage) vs four in the laparotomy group. CONCLUSION: Laparoscopic CRS combined with HIPEC is feasible and safe for curative treatment of strictly selected patients with peritoneal surface malignancy and might reduce postoperative complications and length of hospital stay.
BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are considered the only curative treatment for many peritoneal surface malignancies. The purpose of this study was to evaluate feasibility and safety of CRS combined with HIPEC by laparoscopy for patients with limited peritoneal disease and to compare postoperative outcomes with those for an open procedure. METHODS: Between January 2011 and November 2012, all patients with low-grade pseudomyxoma peritonei (PMP) or multicystic mesothelioma (MM) and limited peritoneal disease (Peritoneal Cancer Index [PCI] less than 10) underwent CRS and HIPEC by a laparoscopic approach. The study cohort was matched with a historical cohort of patients with the same characteristics (completeness of cytoreduction, HIPEC agent, PCI ± 11 and age ± 20 years) treated with CRS and HIPEC by laparotomy. RESULTS: Eight patients (five low-grade PMP and three MM) treated by a laparoscopic approach were compared to eight patients treated by laparotomy. All patients underwent complete cytoreductive surgery with HIPEC, and no conversion to laparotomy was needed. The median surgical length was 210 min (150-300) vs 240 (210-360), with a median hospital stay of 12 days (9-18) vs 19 (13-33). One patient had a postoperative complication (intraperitoneal haematoma treated by radiological drainage) vs four in the laparotomy group. CONCLUSION: Laparoscopic CRS combined with HIPEC is feasible and safe for curative treatment of strictly selected patients with peritoneal surface malignancy and might reduce postoperative complications and length of hospital stay.
Authors: Tali Shaltiel; Daniel Solomon; Eric R Pletcher; Benjamin J Golas; Deepa R Magge; Umut Sarpel; Daniel M Labow; Noah A Cohen Journal: Surg Endosc Date: 2022-01-26 Impact factor: 3.453
Authors: A Arjona-Sanchez; J Esquivel; O Glehen; G Passot; K K Turaga; D Labow; S Rufian-Peña; R Morales; K van der Speeten Journal: Surg Endosc Date: 2018-07-12 Impact factor: 4.584
Authors: A Arjona-Sanchez; S Rufian-Peña; J M Sanchez-Hidalgo; A Casado-Adam; A Cosano-Alvarez; J Briceño-Delgado Journal: World J Surg Date: 2018-10 Impact factor: 3.352
Authors: E Halkia; A Tsochrinis; D T Vassiliadou; A Pavlakou; A Vaxevanidou; A Datsis; E Efstathiou; J Spiliotis Journal: Int J Surg Oncol Date: 2015-02-15
Authors: Turki Alshammari; Sulaiman Alshammari; Riyadh Hakami; Abdullah Alharbi; Mohammad Alyami; Maha Abdulla; Thamer Bin Traiki Journal: Am J Case Rep Date: 2019-11-09